Static.cambridge.org
Supplementary Table S1: Study, Patient and Treatment Characteristics
Supplementary Table S2: Risk of Bias Assessment: Ketamine and Non-Ketamine Studies
Supplementary Fig. S1: Search Results
Supplementary Fig. S2: Ketamine Studies, All Cause Discontinuation, Random Effects Model
Supplementary Fig. S3: Non-Ketamine NMDAR Antagonist Studies, All Cause Discontinuation, Random Effects Model
Supplementary Fig. S4: Ketamine Studies, BPRS, Random Effects Model
Supplementary Fig. S5: Non-Ketamine NMDAR Antagonist Studies, BPRS, Random Effects Model
Supplementary Fig. S6. Ketamine Studies, YMRS, Random Effects Model
Supplementary Fig. S7: Ketamine Studies, CADSS, Random Effects Model
Supplementary Fig. S8: Ketamine Studies, Other Adverse Events, Random Effects Model
Supplementary Fig. S9: Non-Ketamine NMDAR Antagonist Studies, Other Adverse Events, Random Effects Model
|Supplementary Table S1. Study, patient and treatment characteristics |
|Study; |
|Sponsor |
|1. Berman et. al. 2000 10; |
|NIMH, VA and Foundation |
|4. Zarate et al. 2012; |
|NIMH |
|7. Singh et al. 2014 2X/week; Janssen |
|10. Preskorn et al. 2008; |
|Pfizer |
|13. Sanacora et al. 2013 24 (study 9); AstraZeneca |
Supplementary Table S2. Risk of bias assessment: ketamine and non-ketamine studies
|Random sequence generation |Allocation concealment |Blinding of participants and personnel |Blinding of outcome assessment |Incomplete outcome data addressed |Selective reporting |Other sources of bias | |Berman 2000 |? |? |? |? |+ |- |+ | |Diazgranados 2010 |+ |? |? |? |+ |- |+ | |Lai 2014 |? |? |- |- |- |- |- | |Murrough 2013 |? |? |+ |+ |+ |- |+ | |Singh 2014
2X/week |? |? |? |? |+ |- |- | |Singh 2014
3X/wek |? |? |? |? |+ |- |- | |Sos 2013 |? |? |? |? |+ |? |+ | |Zarate 2006 |+ |? |? |? |+ |- |+ | |Zarate 2012 |+ |? |? |? |+ |- |+ | |Subtotal Ketamine |Low risk=3 (33.3%)
Unclear=6 (66.7%) |Unclear=9 (100%) |Low risk=1
(11.1%)
Unclear=7 (77.8%)
High risk=1
(11.1) |Low risk=1
(11.1%)
Unclear=7 (77.8%)
High risk=1
(11.1%) |Low risk=8 (88.9%)
High risk=1 (11.1%) |Unclear=1 (11.1%)
High risk=8
(88.9%) |Low risk=6 (66.7%)
High risk=3
(33.3%) | |Preskorn 2008 |? |? |- |+ |- |? |- | |Preskorn 2015 |? |? |? |? |- |- |+ | |Sanacora 2014 study 1 |? |? |? |? |- |+ |+ | |Sanacora 2014 study 9 |? |? |? |? |+ |- |+ | |Zarate 2013 |+ |? |+ |? |+ |- |+ | |Subtotal Non-Ketamine |Low risk=1 (20%)
Unclear=4 (80%) |Unclear=5 (100%) |Low risk=1 (20%)
Unclear=3 (60%)
High risk=1
(20%) |Low risk=1 (20%)
Unclear=4 (80%) |Low risk=2 (40%)
High risk=3
(60%) |Low risk=1 (20%)
Unclear=1 (20%)
High risk=3
(60%) |Low risk=4 (80%)
High risk=1
(20%) | |Total |Low risk=4 (28.6%)
Unclear=10 (71.4%) |Unclear=14 (100%) |Low risk=2 (14.3%)
Unclear=10 (71.4%)
High risk=2
(14.3%) |Low risk=2 (14.3%)
Unclear=11 (78.6%)
High risk=1
(7.1%) |Low risk=10
(71.4%)
High risk=4
(28.6%) |Low risk=1 (7.1%)
Unclear=2
(14.3%)
High risk=11
(78.6%) |Low risk=10 (71.4%)
High risk=4
(28.6%) | |
+ : Low risk of bias, - : High risk of bias, ? : Unclear risk of bias, nd : not determined
Supplementary Fig. S1. Search results
Supplementary Fig. S2. Ketamine studies, all cause discontinuation, random effects model
[pic]
Supplementary Fig. S3. Non-ketamine NMDAR antagonist studies, all cause discontinuation, random effects model
[pic]
Supplementary Fig. S4. Ketamine studies, BPRS, random effects model
[pic]
Supplementary Fig. S5. Ketamine studies, YMRS, random effects model
[pic]
Supplementary Fig. S6. Ketamine studies, CADSS, random effects model
[pic]
Supplementary Fig. S7. Non-ketamine NMDAR antagonist studies, BPRS, random effects model
[pic]
Supplementary Fig. S8. Ketamine studies, other adverse events, random effects model
[pic]
Supplementary Fig. S9. Non-ketamine NMDAR antagonist studies, other adverse events, random effects model
[pic]
-----------------------
Records identified through database searching
(N=1571 )
Studies identified through hand searching and scientific poster session
(N=3 )
Identification
Included
Eligibility
Screening
Full-text articles and posters assessed for eligibility
(N=26)
Records excluded
(N=1506)
Records screened
(N=26)
Records after duplicates removed
(N=1532)
Articles excluded (N=14):
Review articles (N=5)
Data based on same sample (N=5)
No available data before the 2nd injection (N=2)
Non randomized studies (N=1)
Non intravenous infusion studies (N=1)
Studies included in quantitative synthesis (meta-analysis)
(N=12 articles; 14 trials)
Studies included in qualitative synthesis
(N=12 articles; 14 trials)
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related searches
- static equilibrium equation
- static equilibrium calculations formula
- static equilibrium physics
- static equilibrium physics problems
- static equilibrium equations lever
- static equilibrium examples
- static equilibrium lab report
- static equilibrium calculator
- static equilibrium physics lab
- moment static equilibrium equation
- static equilibrium equations
- dynamic and static equilibrium physics